20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
The STEADY-PD Trial Results
Cure Parkinson’s recently approved funding for a project with Associate Professor Antony Cooper, Garvan Institute, Sydney. The project aimed to determine if there is a group of people with idiopathic Parkinson’s (where the cause is unknown) who have a deficiency of their GBA enzyme GCase (glucocerebrosidase)…
Revising our approach to treating Parkinson’s
The Krembil Knowledge Gaps in Parkinson’s Disease Symposium held in Toronto in April 2019 addressed some of the fundamental questions for further advancing Parkinson’s research. Key among the topics for discussion was the current thinking of Parkinson’s as a single condition or a syndrome of multiple diseases,…
Herantis Pharma: Phase 1/2 CDNF topline results
We are delighted that Finnish-based Herantis Pharma Plc have announced that their ongoing phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint of safety and tolerability. In pre-clinical studies, CDNF has…
Earlier diagnosis and treatment of Dementia in Parkinson’s
A research team at the UCL Queen Square Institute of Neurology – led by Dr Rimona Weil – has recently published research that suggests the monitoring of levels of iron in the brain might eventually help predict which people with Parkinson’s will go on to…
UDCA and laboratory cell-based Parkinson’s
There is a great deal of variability between individuals with Parkinson’s in terms of features like symptoms and speed of disease progression. Given these differences, many researchers believe that we may not be dealing with a single condition, but rather a ‘syndrome’ – that is,…